anthracis. The mortality rates for each manifestation are as follows: approximately 20% for cutaneous anthrax without antibiotics, 25 - 75% for gastrointestinal anthrax, and inhalation anthrax has a fatality rate that is 80% or higher. Cutaneous anthrax can usually be successfully treated with antibiotics and some antibiotics have also been approved for post-exposure prophylaxis [13]. The case fatality ratio for patients with appropriately treated cutaneous anthrax is usually less than 1%. However, for inhalation or gastrointestinal disease fatality can exceed 50%. Case-fatality rates for inhalation anthrax are high, even with appropriate antibiotics and supportive care. Among the eighteen cases of inhalation anthrax in the United States during the twentieth century, the overall case fatality was greater than 85%. Following the bioterrorist attack in fall 2001, the case-fatality rate among patients with inhalation disease (all of whom received antibiotic therapy and aggressive supportive care) was 45% (5/11). The exact case-fatality rate of gastrointestinal anthrax is unknown but is estimated to be 25%-60% [14]. Therefore, anthrax disease has been proven to be deadly in each manifestation. B. anthracis will invade the hosts’ immune cells, macrophages, and release edema toxin (ETx) and lethal toxin (LTx). These toxins will paralyze important biochemical pathways, which will lead to cell …show more content…
anthracis. One way to diagnose cutaneous anthrax is by skin testing. This procedure is completed by taking a sample of fluid from a suspicious lesion on your skin, or by taking a biopsy of a small tissue sample to be tested in a lab for signs of cutaneous anthrax. Another way to test for B. anthracis is by testing a sample of the patient’s blood in a lab for the bacteria. A test that can be done to diagnose inhalation anthrax is a chest X-ray or computerized tomography (CT) scan. One way to diagnose gastrointestinal anthrax is by testing a sample of the patient’s stool to check for B. anthracis